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Interactions between kidney disease 
and diabetes: dangerous liaisons
Roberto Pecoits‑Filho1*, Hugo Abensur2, Carolina C. R. Betônico3, Alisson Diego Machado2, Erika B. Parente4, 
Márcia Queiroz2, João Eduardo Nunes Salles4, Silvia Titan2 and Sergio Vencio5
Abstract 
Background: Type 2 diabetes mellitus (DM) globally affects 18–20 % of adults over the age of 65 years. Diabetic 
kidney disease (DKD) is one of the most frequent and dangerous complications of DM2, affecting about one‑third of 
the patients with DM2. In addition to the pancreas, adipocytes, liver, and intestines, the kidneys also play an impor‑
tant role in glycemic control, particularly due to renal contribution to gluconeogenesis and tubular reabsorption of 
glucose.
Methods: In this review article, based on a report of discussions from an interdisciplinary group of experts in the 
areas of endocrinology, diabetology and nephrology, we detail the relationship between diabetes and kidney disease, 
addressing the care in the diagnosis, the difficulties in achieving glycemic control and possible treatments that can be 
applied according to the different degrees of impairment.
Discussion: Glucose homeostasis is extremely altered in patients with DKD, who are exposed to a high risk of both 
hyperglycemia and hypoglycemia. Both high and low glycemic levels are associated with increased morbidity and 
shortened survival in this group of patients. Factors that are associated with an increased risk of hypoglycemia in DKD 
patients include decreased renal gluconeogenesis, deranged metabolic pathways (including altered metabolism 
of medications) and decreased insulin clearance. On the other hand, decrease glucose filtration and excretion, and 
inflammation‑induce insulin resistance are predisposing factors to hyperglycemic episodes.
Conclusion: Appropriate glycaemic monitoring and control tailored for diabetic patients is required to avoid hypo‑
glycaemia and other glycaemic disarrays in patients with DM2 and kidney disease. Understanding the renal physiol‑
ogy and pathophysiology of DKD has become essential to all specialties treating diabetic patients. Disseminating this 
knowledge and detailing the evidence will be important to initiate breakthrough research and to encourage proper 
treatment of this group of patients.
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Background
The prevalence and incidence of diabetes mellitus (DM) 
has increased significantly worldwide, mainly due to 
a higher prevalence of type 2 DM. Type 2 DM glob-
ally affects 18–20  % of adults over the age of 65  years. 
It is estimated that approximately 285 million people, 
between 20 and 79  years old, currently have DM, 70  % 
of whom live in middle- and low-income countries. This 
increase in type 2 DM (DM2) occurs disproportionately, 
affecting mainly developing countries, thus bringing 
enormous challenges in the public health care for these 
patients. The expectation is for this number to increase 
by more than 50  % over the next 20  years if preventive 
programs are not implemented. By 2030, it is estimated 
that almost 438 million people, or 8 % of the adult popu-
lation, will have DM [1].
Diabetic kidney disease (DKD) is one of the most fre-
quent and dangerous complications of DM2, affecting 
about one-third of the patients. In addition to the increas-
ing complexity of outpatient care for patients with DM, 
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DKD results in increased hospitalizations and mortal-
ity rates, especially due to cardiovascular complications. 
DKD also increases the demand for renal replacement 
therapies, such as dialysis and kidney transplants. The 
combined economic and social costs of this disease are 
high and of concern to the world’s health systems.
Methods
In this review article, based on a report of discussions 
from an interdisciplinary group of experts in the areas 
of endocrinology, diabetology and nephrology, we detail 
the relationship between diabetes and kidney disease, 
addressing the care in the diagnosis, the difficulties in 
achieving glycemic control and possible treatments 
that can be applied according to the different degrees of 
impairment.
Topics explored include pathophysiology, diagnos-
tic measures, pharmacological and nonpharmacologi-
cal treatments, and recommendations based on special 
considerations.
Discussion
The discussion was divided into topics.
Pathophysiology of type 2 DM
DM2 is a disease characterized by persistent hyperglyce-
mia, resulting from partial or complete insulin deficiency, 
and it is associated with a clinical picture of insulin resist-
ance. Recently, other organs have been recognized as 
being involved in the pathogenesis of hyperglycemia in 
DM2, and it now known that not only dysfunction of the 
pancreas, but also of the liver, adipose tissue, intestine, 
kidneys, and central nervous system may contribute to 
this hyperglycemic state [2].
Insulin resistance (IR) is one of the pillars dictating the 
pathogenesis of DM2 and may differ according to body 
tissues. However, where does IR begin? Some authors 
argue it starts in the liver, others in the muscle, and oth-
ers in the brain. What we know is that IR is present in 
various body tissues (liver, peripheral muscle, central 
nervous system, adipocytes, etc.) of patients with DM2, 
preventing glucose to entry into the cell and causing 
hyperglycemia. Several studies show that insulin has 
an anorexigenic action in the central nervous system 
[3–5]. However, the caloric intake in obese individuals is 
enhanced even in the presence of hyperinsulinemia, sug-
gesting a clinical picture of IR in the brain [2]. Regarding 
peripheral IR, it is well established that IR directly cor-
relates with deposits of visceral [6] and intramyocellular 
(within the myocyte) fat [7, 8]. This can be explained by 
the inflammatory role of adipocytes in producing inter-
leukin-6 and tumor necrosis factor-α, among other pro-
inflammatory substances that alter intracellular signaling 
through the insulin receptor and consequently decrease 
the expression of glucose transporters of the cell mem-
brane (GLUTs), leading to IR. In the muscle, when dep-
osition of intramyocellular fat occurs, especially in the 
cytoplasm far from mitochondria, cytoplasmic diacylg-
lycerol production increases, which leads to a decreased 
membrane expression of GLUT4, subsequent reduction 
of muscle glucose uptake, and hyperglycemia [7].
Hyperglycemia is not observed in a clinical picture of 
impaired glucose tolerance or pre-diabetes, since hyper-
insulinemia can still compensate for IR and maintain 
normal levels of blood glucose. When hyperinsulinemia 
can no longer compensate for IR and insulin secretion 
begins to decline, the disruption of these variables results 
in hyperglycemia and a diagnosis of DM. In the early 
stages of DM2, the clinical picture of hyperinsulinemia 
persists. However, reduced insulin secretion is mainly 
responsible for the clinical picture of hyperglycemia. In 
the later stages of the disease, IR persists. However, the 
clinical picture, characterized by deficient insulin secre-
tion, worsens, thus exacerbating the loss of glycemic 
control.
The gold standard to evaluate insulin resistance is the 
euglycemic insulin clamp technique. However, this tech-
nique is difficult to perform, expensive to apply, and 
is only used in clinical studies [9]. More simply, we can 
estimate IR using formulas that correlate with the clamp, 
such as the homeostatic model assessment (HOMA-
IR): [fasting insulin (mU/mL)  ×  fasting blood glucose 
(mmol/L)]/22.5 [10]. It is important to remember that 
HOMA-IR assesses hepatic IR, as the calculation involves 
the use of fasting blood glucose and insulin levels. On the 
other hand, the Matsuda index can estimate hepatic and 
peripheral insulin sensitivity, using glycemia and insu-
linemia values obtained through an oral glucose toler-
ance test [11].
In addition to IR, insulin deficiency is essential to man-
ifest hyperglycemia in DM2. There are several factors 
involved in the process of insulin secretion, and incre-
tins are one of the most important. Incretins are hor-
mones secreted by the gut that have different functions 
upon binding to their receptors, expressed in various 
organs and tissues. After a meal, 60  % of insulin secre-
tion depends on the stimulation of incretin hormones 
[12]. There are two main incretins: glucose-dependent 
insulinotropic peptide (GIP) and glucagon-like pep-
tide-1 (GLP-1). Both are involved in glucose homeosta-
sis. However, GLP-1 is more important than GIP, since it 
also inhibits glucagon secretion, slows gastric emptying, 
and inhibits hunger, whereas GIP does not [13]. There-
fore, GLP-1 is a target of several incretin therapies for 
the treatment of DM2. GLP-1 is secreted by the L-cells 
of the ileum and has a half-life of 2 min; it is inactivated 
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by dipeptidyl dipeptidase-4 enzyme [13]. When released 
into the circulation, GLP-1 binds to its receptor, which 
is expressed in different tissues, and promotes differ-
ent actions. The GLP-1 receptor is a G-protein-coupled 
receptor, and binding activates adenylyl cyclase, leading 
to a subsequent increase in cyclic adenosine monophos-
phate, which activates protein kinase A and increases 
the release of insulin [14]. It is worth noting that incre-
tins stimulate glucose-dependent insulin secretion, i.e., 
only if blood glucose is elevated. The GLP-1 receptor is 
expressed in multiple organs besides the pancreas, such 
as the intestine, kidneys, heart, and central nervous sys-
tem. It exerts different functions in different tissues: (1) 
in the central nervous system, it decreases hunger and 
increases satiety; (2) in the pancreas, after a meal, it stim-
ulates insulin secretion from β cells and decreases the 
release of glucagon by α cells; (3) in the liver, it reduces 
glycogenolysis and gluconeogenesis by decreasing post-
prandial glucagon; (4) in the heart, it plays a cardiopro-
tective role; and (5) in the vessels, it acts as a vasodilator 
[15].
Patients with DM2 have an impaired incretin system, in 
addition to the dysfunction of β and α cells. A decreased 
effect of incretins affects not only the secretion of insulin, 
but also other beneficial effects promoted via the GLP-1 
receptor. This supports several modern proposed DM2 
pharmacological therapies aimed at improving the effects 
of incretins.
In addition to the pancreas, adipocytes, liver, and intes-
tines, the kidneys also play important roles in glycemic 
control. In the tubular reabsorption of glucose, renal 
gluconeogenesis also contributes significantly to glu-
cose homeostasis. By 1938, the first studies [16] on the 
role of the kidney in glycemic control were conducted in 
animals, and in the late 1950s, studies on renal glucose 
metabolism were conducted in humans [17–20]. Several 
hormones are involved in regulating renal reabsorption 
of glucose: hyperinsulinemia blocks the secretion of renal 
glucose as it does in the liver [21, 22]. However, epineph-
rine infusion increases the release of renal glucose [23], 
and this effect is not altered by glucagon [24]. Although 
there is not yet available data in humans, several studies 
suggest that cortisol and growth hormone may stimulate 
the release of renal glucose [25, 26].
Renal blood flow averages 1000–1500  mL/min, and 
in healthy individuals, all filtered glucose is reabsorbed 
by the renal tubules [27]. On average, the kidneys filter 
162  g of glucose per day (considering a glomerular fil-
tration rate of 180 L/day); 90 % of this is reabsorbed via 
the sodium/glucose cotransporter (SGLT) 2 expressed 
in the proximal tubule. The remaining 10  % of filtered 
glucose is absorbed by the SGLT1 transporter located in 
the descending proximal tubule, thus usually preventing 
glycosuria [2]. In individuals with DM, the Tm for glu-
cose (maximum capacity of renal tubular reabsorption of 
glucose) is higher than in healthy individuals, thus wors-
ening hyperglycemia. On average, the kidneys contrib-
ute 20  % of total body glucose through glucose tubular 
reabsorption and renal gluconeogenesis [27]. Because the 
kidneys play a role in glucose homeostasis, therapies have 
been developed to reduce tubular reabsorption of glu-
cose, which is achieved by inhibition of the SGLT2 trans-
porter. Other therapies suppress both SGLT2 and SGLT1, 
with the aim of improving glycemia by increasing glyco-
suria. Unlike previous views regarding glycosuria, after 
the introduction anti-SGLT1 and -SGLT2 medications in 
the treatment of DM2, glycosuria has become a desired 
clinical sign.
Glucose homeostasis in kidney disease
Glucose homeostasis is extremely altered in patients with 
CKD, who are exposed to a high risk of both hypergly-
cemia and hypoglycemia. Both high and low glycemic 
levels are associated with increased morbidity and short-
ened survival in this group of patients. Factors that are 
associated with an increased risk of hypoglycemia in 
CKD patients include decreased renal gluconeogenesis, 
deranged metabolic pathways (including altered metabo-
lism of medications) and decreased insulin clearance. On 
the other hand, decrease glucose filtration and excretion, 
and inflammation-induce insulin resistance are predis-
posing factors to hyperglycemic episodes (Fig. 1). Appro-
priate glycaemic control tailored for diabetic patients is 
required to avoid haemodialysis-induced hypoglycaemia 
and other glycaemic disarrays [28].
Glycemic monitoring in CKD
As lack of glycemic control increases the rate of pro-
gression of renal failure, proper glycemic control in the 
early stages of CKD is crucial [29]. The United Kingdom 
Prospective Diabetes Study (UKPDS) provided the first 
evidence that intensive glycemic control, determined by 
a more aggressive therapy combined with monitoring 
and more frequent medical follow-up, could reduce the 
long-term complications caused by DM2 [30]. Although 
hyperglycemia is the biochemical marker of DM, hemo-
globin A1c (HbA1c) has slowly become the cornerstone 
for the diagnosis and monitoring of DM since its intro-
duction into routine clinical practice in 1976 [31]. There 
are confounding factors in the measurement of HbA1c, 
among which we have previously reported the differ-
ence in intracellular-extracellular glucose homeostasis, 
the survival time of red blood cells (hemolytic anemia), 
and non-glycemic genetic determinants of hemoglobin 
glycation. For this reason, the use of HbA1c as the only 
criterion for the diagnosis of DM in non-Caucasian 
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individuals can lead to misclassification. In addition to its 
recent role as a diagnostic marker, HbA1c is also used to 
evaluate the degree of metabolic control in diabetics and 
to predict the risk of vascular complications [32, 33].
There is conflicting evidence on the role of HbA1c in 
reflecting long-term glycemic control in patients with 
CKD. Moreover, the association between glycemic con-
trol and outcomes may be different in patients with or 
without CKD. Uremia causes a unique internal environ-
ment, which creates the need to assess each case in a 
personalized manner. Therefore, markers for monitoring 
glycemic control, specifically in individuals with CKD, 
need to be evaluated [34].
Glucose monitoring for the prevention of acute and 
chronic complications is critical in the management of 
DM. Therefore, we will discuss the main markers for gly-
cemic control and their limitations in patients with CKD.
Blood glucose concentration
According to biological variation, in order to avoid 
patients misclassification, glucose measurement should 
have an analytical imprecision ≤2.9 %, a bias ≤2.2 %, and 
a total error ≤6.9 %. In a perfect scenario, glucose analy-
sis should minimize total analytical error, and methods 
should be without measurable bias [35].
Enzymatic methods for glucose analysis are well stand-
ardized. A survey conducted by the College of American 
Pathologists (CAP) reveals that hexokinase or glucose 
oxidase is used in nearly all analyses performed in the 
U.S. few laboratories use glucose dehydrogenase. Glucose 
is stable for 8 h in samples collected with an antiglycolytic 
agent. In plasma, serum, and other liquids already sepa-
rated from cells, the level of glucose is stable for 3 days at 
2–8 °C if there is no bacterial contamination [36].
Important factors interfering with  glucose measure-
ment Bilirubin levels >10 mg/dL produce negative inter-
ference when the endpoint method is utilized. For samples 
containing triglyceride concentrations >1100 mg/dL, the 
turbidity effect can be minimized using by diluting it with 
NaCl 150  mmol/L (0.85  %) and repeating the measure-
ment. Bilirubin levels ≤10 mg/dL, hemoglobin ≤150 mg/
dL, and triglycerides ≤3500  mg/dL do not produce sig-
nificant interference when the kinetic method is used. 
Ascorbic acid at concentrations >100 mg/dL also interfere 
with the reaction, producing falsely low results [36].
Preparation for the exam The collection should be pre-
ceded by a fasting period of 8–12  h, with water intake. 
Physical activity and a habitual diet are recommended the 
day before the examination as well as a standard diet of 
150 g carbohydrates [36].
Home glucose monitoring or self‑monitoring (SM)
SM is a valuable resource for both the patient and the 
doctor, as it is undoubtedly among the markers for 
Fig. 1 Chronic kidney disease mechanisms predisposisng to hyperglycaemia and hypoglycaemia
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glycemic control that provide the greatest amount of 
information about daily nutrition and the resultant gly-
cemic responses. Pimazzoni et al. established several cri-
teria that must be followed in order to produce favorable 
results, optimizing the use of SM [37]:
  • The patient should be instructed regarding the 
proper use and benefits provided by the correct SM 
practice.
  • The patient should follow a continued practice of DM 
education, not only in the initial discovery of the dis-
ease but also as the disease evolves.
  • There is no frequency of tests that can be recom-
mended to all patients. On the contrary, this fre-
quency should be individualized and adapted to the 
clinical conditions of each patient.
  • The SM results should be effectively used by the phy-
sician and other health professionals, to promote 
constant adjustments in the therapeutic conduct and 
supplementary guidance of nursing, nutrition, psy-
chology, and physical education.
SM does not interfere with monitoring in diabetic 
patients with CKD. Its limitations include the need for 
training and economic access to tapes. However, there is 
no doubt that establishing a pattern of glycemic variation 
is fundamental. The importance of glycemic variability 
as an isolated factor for cardiovascular risk is well estab-
lished [38]. Another important parameter regarding SM 
is the potential to download the information on specific 
software, generating accompanying graphs that facilitate 
understanding and decision-making.
Glycated hemoglobin
Glycation is a nonenzymatic reaction of glucose binding 
to a protein, in this case, to hemoglobin, yielding glycated 
hemoglobin, or HbA1c. In keeping with this notion, the 
term glycosylated hemoglobin is incorrect. The generic 
term “glycated hemoglobin” refers to a group of sub-
stances formed from the reactions between hemoglobin 
A (HbA) and certain sugars. This process is concentra-
tion- and time-dependent. In practical terms, this means 
that the greater the concentration of glucose available, 
the higher the concentration of HbA1c. In contrast, over 
time, there is a lower the binding of glucose to hemo-
globin [39].
In contrast to plasma glucose, HbA1c represents non-
enzymatic glycation, which depends on the concentra-
tion of glucose in the intra-erythrocytic compartment. 
Although several studies found a good positive correla-
tion between the concentrations of HbA1c and glucose 
in diabetic patients with and without CKD, the variable 
relationship between HbA1c and estimated average glu-
cose remains a potential source of concern [40].
It is interesting to notice that, normally, 97 % of hemo-
globin is HbA. Only 6  % of HbA undergoes a glycation 
process and becomes HbA1c. Ninety-four percent of 
HbA undergoes no action induced by any sugars and is 
called HbA0. In turn, HbA1c is divided into subtypes 
in accordance with the type of sugar that produces gly-
cation. Twenty percent of HbA1c is influenced by fruc-
tose-1,6-diphosphate and glucose-6-phosphate, forming 
HbA1a and HbA1b. The remaining 80  % of HbA1c is 
glycated dependent upon glycemic variation and is called 
HbA1c [39].
Main laboratory methods used The following methods 
are approved by the National Glycohemoglobin Stand-
ardization Program (NGSP): high performance liquid 
chromatography (HPLC—a method that was applied in 
the diabetes control and complications trial (DCCT)), 
boronic acid affinity chromatography, enzymatic, immu-
noassay, and capillary electrophoresis. Since different 
methods quantify different ratios of glycated hemoglobin, 
the results are different. However, an excellent correlation 
was observed in a sample without hemoglobin variants 
or the presence of interfering factors. Through NGSP, the 
values of glycated hemoglobin can be expressed to provide 
equivalent results of the glycemic status of the patient, 
regardless of the method used, thus the same criteria can 
be widely applied. NGSP standardized these methods for 
the results to be comparable to those obtained by DCCT, 
in which the relationship between the average levels of 
blood glucose and the risk for vascular complications was 
established. A list of methods and worldwide laboratories, 
the certification of which depends on the demonstration 
of an acceptable accuracy and compliance with DCCT 
standards, is also provided on their website (http://www.
ngsp.org) [41].
Important factors causing technical interference Inter-
ference in the dosage of HbA1c might occur and depends 
on the method used: factors increasing HbA1c measure-
ments include renal impairment (increased urea binds 
to hemoglobin, producing carbamylated hemoglobin 
that interferes with HbA1c measurement); use of acetyl-
salicylic acid (binds to hemoglobin, producing acetylated 
hemoglobin, which interferes with HbA1c measurement; 
usually, this occurs with high doses of acetylsalicylic acid); 
hypertriglyceridemia; and hyperbilirubinemia. Finally, fac-
tors decreasing HbA1c measurements include hemoglobin 
glycation inhibition factors (e.g., vitamins C and E) [42].
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Clinical conditions that interfere with the method Inter-
ference might occur with the dosage of HbA1c, depending 
on the method: factors increasing HbA1c measurements 
include polycythemia, anemia due to iron deficiency, folic 
acid, or vitamin B12; chronic alcoholism; and opiates. Fac-
tors decreasing HbA1c measurements include conditions 
that shorten the half-life of red blood cells (e.g., hemolytic 
anemia, hemorrhages), lead poisoning, erythropoietin 
deficiency secondary to renal failure, multiple myeloma, 
hyperthyroidism, leukemia, and severe burns with loss of 
fluid and proteins [42].
Fasting is not necessary for the collection of the material. 
Whole blood collected using EDTA as anticoagulant. The 
blood can be stored in a refrigerator for a week. Heparin-
ized samples should be assayed in a maximum of 48 h [41].
Limitations of glycated hemoglobin in CKD In addition 
to glucose, other factors might also influence HbA1c: 
this is the main reason for which the dosage of HbA1c 
is questioned in patients with CKD. Among these influ-
ences, we highlight a few. First, the formation of HbA1c 
is dependent on the interaction (intensity and duration) 
between the concentrations of glucose and blood erythro-
cytes. On average, erythrocytes survive 117 days in men 
and 106 days in women. At a certain point, a blood sample 
contains erythrocytes of different ages, mainly younger 
elements and with different degrees of exposure to hyper-
glycemia [40]. HbA1c is a measure for the mean level of 
blood glucose in the past 90 days. The impact of recent 
blood glucose levels on the measurement of A1c are: 50 % 
for the last month, 25 % for the 2nd month ago, and 25 % 
for the 3rd and 4th month ago.
An unexplained discrepancy between HbA1c and other 
measurements of glycemic control can be partly due to 
the different life span of erythrocytes. Decreased eryth-
ropoiesis, caused by iron or vitamin B12 deficiency or 
aplastic anemia, leads to an increased number of aged 
red blood cells and a subsequent progressive increase of 
HbA1c, unrelated to glycemic control [43].
Anemia due to iron deficiency increases HbA1c up 
to 2 %, which can be reverted by iron supplementation. 
Conversely, a decrease in HbA1c is observed after the 
administration of erythropoietin, iron, and vitamin B12, 
and in cases of hemolytic anemia. Due to a reduction in 
the survival of red blood cells, younger erythrocytes have 
less time to be exposed to a glycemic environment and 
therefore undergo less glycation [44] Hemoglobinopa-
thies, of which the most common example is sickle cell 
anemia and thalassemia, can lead to problems in the 
interpretation of HbA1c. In case of these changes, in 
addition to the normal HbA0 glycation to form HbA1c, 
other glycation products derived from HbC (African 
populations), HbD (indigenous populations), HbE (Asian 
populations), or HbS (sickle cell anemia) could be formed 
[43].
In the third National Health and Nutrition Examina-
tion Survey, alcohol consumption was associated with 
low levels of HbA1c in 1024 adults with DM. These find-
ings were confirmed in a large follow-up study of 38,564 
adult patients with type 1 or 2 DM. An increase in alco-
hol consumption predicts lower HbA1c values. Also, the 
intra-erythrocytes pH can interfere HbA1c. In patients 
with chronic renal failure, lipid peroxidation of Hb can 
increase hemoglobin glycation. Chronic ingestion of 
aspirin and high doses of antioxidants (e.g., vitamins C 
and E) may reduce HbA1c, since they inhibit glycation. It 
is unclear whether these phenomena could change clini-
cal practice [45].
In addition to the changes described above, it is 
important to highlight that new methods detect differ-
ently the presence of hemoglobinopathies, and the pres-
ence of carbamylated hemoglobin can interfere with the 
dosage. HbA1c measured by HPLC detects the carba-
mylated fraction differently than does immunoturbidim-
etry, which does not identify this fraction; consequently, 
patients with renal failure present higher levels of HbA1c 
when measured using HPLC [44].
Glycated albumin
The dosage of glycated albumin (GA) is gaining inter-
est as a potential marker of glycemic control. GA is a 
ketoamine formed by the non-enzymatic oxidation of 
albumin by glucose. As the half-life of albumin is of 
approximately 15 days, GA is used as a short-term meas-
urement of glycemic control, that is, 2–3  weeks, and as 
such, it might act as an intermediate time index of glyce-
mic control [44].
Several methods can be used for the measurement of 
GA, including affinity chromatography, ion-exchange 
chromatography, HPLC, immunoassay techniques, capil-
lary electrophoresis, and other electrophoretic and enzy-
matic assays. It is not influenced by sex, red blood cell life 
span, or erythropoietin therapy; however, for serum albu-
min concentration, the results are conflicting [46].
However, the results can be influenced by age, nutri-
tional status, albuminuria, cirrhosis, thyroid dysfunction, 
and smoking. GA is inversely influenced by body mass 
index, body fat mass, and visceral adipose tissue [46].
Glycated fructosamine
Fructosamine is the generic name given to all glycated 
proteins, of which albumin is the major plasma fraction, 
after hemoglobin. Although the dosage of fructosamine 
can be automated, thus making it cheaper and faster than 
HbA1c measurement, there is no consensus on its clini-
cal utility [47].
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The level of fructosamine correlates better with the 
average glucose levels over the previous 10–14  days. 
As this is a measure of total glycated serum proteins, of 
which glycated albumin represents approximately 90  %, 
fructosamine concentrations can be influenced by the 
concentrations of serum proteins and the profile of dif-
ferent proteins [47].
Moreover, fructosamine is influenced by the concen-
tration of bilirubin and substances with low molecular 
weight, such as urea and uric acid. GF is not modified by 
changes in the metabolism of hemoglobin. However, it is 
affected by disturbances in protein turnover. The refer-
ence values depend on age, sex, sample population, and 
test method applied [48].
Unfortunately, the data show conflicting results con-
cerning the correlation between fructosamine and glu-
cose concentrations in patients with CKD. The values 
may be influenced by nephrotic syndrome, thyroid dis-
eases, administration of glucocorticoids, liver cirrhosis, 
and jaundice [48].
1,5‑Anhydroglucitol (1.5‑AG)
1.5-AG is another blood glucose marker and is a natu-
rally occurring dietary plasma polyol, for which levels are 
maintained constant during normoglycemia by filtration 
and renal reabsorption. The physiological function and 
metabolism of 1,5-AG are not well defined. 1,5-AG is a 
non-metabolizable glucose analog found in plasma after 
food intake. It is characterized by urinary excretion, fil-
tration through the glomeruli at a rate of 5–10 g/L, and 
high tubular reabsorption (>99 %), which is inhibited by 
glucose during periods of hyperglycemia [49].
The levels of 1,5-AG in blood are altered less than 24 h 
after hyperglycemic episodes, and the repetition of these 
episodes dramatically decreases its concentration. The 
values of 1,5-AG reflect hyperglycemia over a period 
of approximately 1  week. In addition to the glycosuria 
threshold, the measurement of 1,5-AG could play an 
adjuvant role in the control of DM, especially as a short-
term single marker for hyperglycemia excursions [50].
The relationship between HbA1c and glucose is more 
complex in more advanced stages of CKD due to the 
great variability in hemoglobin, nutritional status, and 
inflammation. Moreover, these underlying comorbidities 
may also hinder the prognostic value of HbA1c [44].
Figure  2 shows the correlation between each marker 
and the time of hyperglycemia that each indicates.
Current guidelines recommend using HbA1c as pre-
ferred biomarker for glycemic control in patients with 
CKD, with a goal of 7 % to prevent or delay the progres-
sion of microvascular complications of DM, including 
diabetic nephropathy [33]. However, these guidelines 
refer mainly to the initial stages of CKD. In diabetic 
patients with advanced disease, it is suggested that the 
objective of a very intensive glycemic control, HbA1c 
<6.5 %, can be associated with increased mortality.
A cohort study assessing 54,757 diabetics on hemodi-
alysis demonstrated that an average HbA1c >8  % or an 
average glucose >200  mg/dL seemed to be associated 
with an increased cardiovascular mortality [51]. A recent 
meta-analysis, investigating the relationship between 
HbA1c and risk of death in diabetic hemodialysis 
patients, showed that the level of HbA1c remains a useful 
clinical tool for the prediction of the mortality risk [52].
Although glycated albumin presents advantages in 
patients with CKD, several authors argue that CKD is 
characterized by the disruption of albumin homeosta-
sis and that the threshold of serum albumin for which 
the risk of death increases varies according to the dialy-
sis modality [53]. In the presence of hypoalbuminemia, 
plasma protein glycation is increased. However, glycated 
albumin seems to reflect the percentage of albumin that 
is glycated, regardless of the concentration of total serum 
albumin, although more studies on a large scale with dial-
ysis patients would be required to confirm this observa-
tion [54].
Glycated albumin seems to be a better marker to reflect 
the accuracy of glycemic control when compared to 
HbA1c in patients with DKD. However, due to limited 
data, the absence of studies on the results of interven-
tions based on glycated albumin and its expensive and 
laborious methodology, indicate that it might be prema-
ture to abandon HbA1c in favor of glycated albumin [55].
Thus, our recommendation is that diabetic patients 
with CKD would be monitored in the best possible way, 
in the attempt to prevent the progression of the disease 
and an increase in complications. Therefore, we suggest 
monitoring HbA1c every 3  months, which can be asso-
ciated with home SM when possible. Other exams such 
as glycated fructosamine, glycated albumin, and 1,5-AG 
could be used as additional tools, rather than replacing 
HbA1c.
General approach of DM treatment in CKD
General considerations for the control of DM in CKD
Glycemic control is fundamental in the prevention and 
progression of complications associated with DM [56, 
57]. Studies show that reducing HbA1c to values ≤7  % 
influences the reduction of microvascular complications 
caused by DM, and if implemented early, it is also associ-
ated with a reduced occurrence of macrovascular compli-
cations [56, 57].
The goals proposed by the Brazilian Diabetes Society 
(SBD) in 2013/2014 Guidelines recommend achievement 
of the following aims: fasting glucose <100  mg/dL, pre-
prandial glycemia <130  mg/dL, postprandial glycemia 
Page 8 of 21Pecoits‑Filho et al. Diabetol Metab Syndr  (2016) 8:50 
≤160 mg/dL [58], and HbA1c <7 %. In 2015, The Ameri-
can Diabetes Association (ADA) reinforced its proposal 
to keep HbA1c optimal values <7  % for most diabetic 
adults [59]. However, in recent years, the associations 
focused on the treatment of DM have systematically 
reviewed the optimal values of glycemia and HbA1c goals 
for diabetic patients, with the aim to define individualized 
objectives to prevent the onset of chronic complications, 
aiming also to reduce the occurrence of hypoglycemia.
The ACCORD (action to control cardiovascular risk 
in diabetes) trial was a landmark in demonstrating that 
patients with high cardiovascular risk, when treated 
intensively with the aim to achieve HbA1c of approxi-
mately 6  %, presented an increased risk of death [60]. 
After this study, associations such as ADA began to rec-
ommend individualized HbA1c goals for patients with a 
history of severe hypoglycemia, limited life expectancy, 
patients with microvascular or macrovascular compli-
cations in advanced stages, and patients with multiple 
comorbidities. The recommendation of less strict HbA1c 
goals (around 8  %) for these groups aims to reduce the 
morbidity and mortality associated with a very strict gly-
cemic control, often related to an increase in hypoglyce-
mic episodes [59].
Specifically in relation to DKD, classical studies have 
also previously demonstrated that improved glycemic 
control is associated with a reduced incidence of albu-
minuria in both type 1 and type 2 DM [56, 57]. Even in 
secondary prevention, i.e., when the kidney disease is 
already established, glycemic control remains a major 
therapeutic weapon to combat the progression of CKD 
[61, 62]. The ADVANCE (action in diabetes and vascu-
lar disease) trial showed that intensive control was able 
to reduce albuminuria, nephropathy, and the need for 
hemodialysis [63]. Similarly, the ACCORD trial showed 
a significant reduction in albuminuria (although not 
in advanced renal disease) in the group treated with an 
intensive therapy for glycemic control [60].
However, despite evidence correlating the optimiza-
tion of glycemic control to the benefits observed in the 
evolution of DKD, glycemic and HbA1c objectives are 
very difficult to define and achieve in this population. The 
complexity of glycemic control in this group of patients 
is explained not only by the metabolic alterations asso-
ciated with DKD, but also the specificity and greater 
difficulty in the use of hypoglycemic drugs, difficulty in 
monitoring glycemic levels, behavioral addictions related 
to years of DM and a fear of hypoglycemia, as well as 
sociocultural and economic factors.
DKD progresses with several metabolic changes, which 
occur concomitantly with the progressive decline in glo-
merular filtration rate (GFR). Using the euglycemic insu-
lin clamp, DeFronzo et al. showed that the glucose used 
by peripheral tissues in response to insulin is reduced in 
uremia [64]. The increased insulin resistance is related to 
the accumulation of uremic toxins, markers of chronic 
inflammation, increased visceral fat, oxidative stress, and 
vitamin D deficiency. Progression to uremia is associated 
with decreased insulin sensitivity of peripheral tissues, 
increased hepatic gluconeogenesis, decreased glucose 
uptake by skeletal muscle cells, and deficiency of intra-
cellular glycogen synthesis and subsequent hyperglyce-
mia [65]. On the other hand, the risk of hypoglycemia 
is a constant concern, since this is increased in diabetic 
patients with CKD. The pathogenesis of hypoglycemia in 
these patients is related to changes in glucose metabo-
lism, decreased insulin degradation, and changes in the 
metabolism of hypoglycemic agents. With a progres-
sive reduction in GFR, we observed a decrease in the 
clearance of oral hypoglycemic agents, and sometimes, 
a longer time of action of these drugs and their active 
metabolites. Similarly, insulin metabolism is also altered, 
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Fig. 2 Correlation between each marker and the time of hyperglycemia that each indicates
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since part of its metabolization and excretion is carried 
out by the renal system [66–68]. A restricted diet, either 
by prescription or even due to uremia, reduces hepatic 
gluconeogenesis, thus contributing to the occurrence of 
hypoglycemic episodes observed at higher frequency in 
this population [69, 70].
Therefore, since CKD is a condition that increases pre-
disposition to hyperglycemic and hypoglycemic peaks, 
the choice of drug treatment for these patients should be 
carefully considered [71–73]. Most classes of oral hypo-
glycemic agents should be avoided when GFR is <40 mL/
min, which indicated a higher risk of hypoglycemia. Insu-
lin is the therapy of choice for the treatment of diabetic 
patients with advanced CKD, and for insulinization to 
occur properly. Adherence and understanding of patients 
are of utmost importance. In phases IV and V of CKD, 
almost all patients with DKD (in which DM is the cen-
tral determinant in the etiology of DKD) need insulin. 
Patients with advanced CKD in which DM is another 
comorbidity, rather than the etiology of CKD, require 
insulin less frequently. Therefore, it is important that 
attending physicians have a broad knowledge of the arse-
nal of oral hypoglycemic agents that are currently availa-
ble, in order to avoid the use of insulin when possible and 
the inappropriate and dangerous use of oral hypoglyce-
mic agents. Oral hypoglycemic agents could also be used 
in patients with burnout syndrome, in which the “disap-
pearance” of DM is almost always observed because of 
important homeostatic changes related to diet restric-
tions, catabolism, weight loss and greater circulation of 
endogenous insulin.
In any case, most patients with advanced CKD need to 
use insulin for the safe and effective control of DM. How-
ever, for this to be achieved, a number of points should 
be discussed with the patient and the family:
  • Proper storage of insulin
  • Application techniques, insulin mixing techniques, 
and rotation of daily application locations
  • Strict diet at pre-determined times
  • Guidelines on how to proceed in the presence of 
hypoglycemia
  • Adherence to multiple daily insulin injections
  • Conduction of pre- and postprandial capillary blood 
glucose tests, also conducted at dawn, facilitating 
dose adjustment.
These guidelines require a commitment not only from 
the patients and their families, but also from a multidisci-
plinary team to make certain that the procedures are ful-
filled. It is known that many diabetic patients who evolve 
towards a progressive loss of renal function have a personal 
history of poor adherence to the treatment, either due to 
inherent factors of the patient or the difficulty of the health 
system in dealing with a complex framework, thus demand-
ing specific care. We also noticed that many patients with 
advanced stage kidney disease often have comorbidities 
that further hamper their adherence to the treatment. 
Patients with diabetic retinopathy (DR) or those who have 
undergone amputation require the support of their families 
for periodic consultations, drug administration, and com-
pletion of capillary blood glucose monitoring tests.
The awareness and motivation of the patients and their 
families to complete the proposed treatment strategies 
in order to achieve the necessary goals for proper meta-
bolic control should always be reviewed and emphasized 
by the multidisciplinary team. It is important that the 
entire team pays attention in identifying the problems 
that can range from understanding the subject, to access 
to information and inadequate use of insulin. These hab-
its are particularly common in patients with a history 
of poor glycemic control caused by self-medication for 
many years or by extreme fear of hypoglycemic episodes 
that led to the use of lower doses of insulin (most often 
not disclosed to the medical team). A condition often 
observed in populations of lower socioeconomic condi-
tions is concurrent very high glycated hemoglobin lev-
els and frequent episodes of hypoglycemia. Therefore, 
the best option is to provide DM re-education, review 
dietary patterns, and ensure fractionation of insulin 
dosage. Often, however, the medical team responds 
inadequately, and insists on increasing the insulin dose, 
which the patient reduces without reporting the decrease 
because of fear of worsening hypoglycemia. This creates 
a complete dissociation between the healthcare team and 
patient, with mutual loss of trust and overall inefficacy 
of the treatment. If this occurs, the process of re-edu-
cation becomes even more important, since in addition 
to directly approaching patients and their families, it 
becomes necessary to work on concepts, insecurities, and 
prescription patterns of the attending medical team.
According to NKF–KDOQI (National Kidney Foun-
dation–Kidney Disease Outcomes Quality Initiative), 
HbA1c objectives in diabetic patients with CKD do not 
differ from those recommended for patients without 
renal disease, aimed to maintain HbA1c values lower 
than 7  % [74–76]. However, as already mentioned, the 
importance of individualization of HbA1c goals has 
already recognized by the ADA [59]. It is noteworthy 
that most diabetic patients with CKD or DKD, in a broad 
sense, fit the ADA’s criteria for high risk of hypoglycemia.
Hypertension, dyslipidemia, and other microvascular 
complications in diabetic patients with CKD
Blood pressure control is fundamental in the manage-
ment of kidney disease progression. In general, diabetic 
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patients with lower blood pressure levels and renal dis-
ease tend to experience slower progression of the pathol-
ogy compared to hypertensive patients with the same 
condition [77]. Non-pharmacological measures (dietary 
changes and increased physical activity) have an impact 
on blood pressure control and should be encouraged. 
Drugs inhibiting the renin-angiotensin system through 
its specific renoprotective effect, regardless of the reduc-
tion in systemic blood pressure, have a well-established 
role in diminishing albuminuria and DKD progression 
[78].
Studies comparing the effect of angiotensin-convert-
ing enzyme (ACE) inhibitors and angiotensin II recep-
tor blockers (ARBs) reported similar effectiveness. 
Therefore, ACE inhibitors or ARBs are recommended 
in patients with CKD, regardless of their ethnicity, as 
first-line treatment or in combination with another 
antihypertensive drugs [79]. Dose adjustment for these 
agents should be gradual, with periodic assessment of 
renal function and potassium levels, since there is a risk 
for creatinine level elevation and hyperkalemia. Greater 
attention must be paid to monitoring elderly patients 
and individuals with advanced stage CKD. In December 
2013, the 8th Joint National Committee of Hyperten-
sion discussed new strategies for blood pressure control, 
and it was recommendation that ACE inhibitors and 
ARBs should not be used in the same patient simultane-
ously due to the following concerning findings: first, the 
VA-NEPHRON D trial [80] was prematurely terminated 
because of concerns about a high prevalence of hypo-
tension, hyperkalemia and acute kidney injury with dual 
renin-angiotensin system (RAS) therapy. Actually, these 
adverse events could have been prevented by avoiding 
forced ACEi up-titration in patients with an eGFR as low 
as 30 mL/min/1.73 m2 on top of full-dose ARB. Notably, 
at study closure dual versus single RAS inhibition had 
already reduced end-stage renal disease events by 34 %, a 
treatment effect never reported before in type 2 diabetes. 
Risk reduction was associated with a significantly greater 
decline in proteinuria and approached nominal signifi-
cance (P = 0.07) over just 2.2 years of follow-up. Second, 
in the RENAAL study [78], performed in type 2 dia-
betic patients, the larger antiproteinuric effect of losar-
tan was associated with a similar (28 %) end-stage renal 
disease reduction compared to placebo. The treatment 
effect was, however, not still appreciable at 2.2 years, but 
became statistically significant over the planned 3.2 years 
of follow up. These data strongly suggest that also in the 
VA NEPHRON-D trial, end-stage renal disease events 
could have been significantly reduced over the initially 
scheduled 5-year study period. Consistently, the results 
of a recent meta-analysis showing that dual RAS block-
ade with ACE inhibition and ARB is the most effective 
strategy to prevent end-stage renal disease in patients 
with diabetes and kidney disease [81].
The development of objectives to achieve adequate 
blood pressure levels to reduce cardiovascular events and 
progression of kidney disease has been the goal of recent 
studies. The ACCORD trial failed to show a reduction in 
cardiovascular events; moreover, in the ACCORD study 
[77], there were significantly more instances of an eGFR 
less than 30  mL/min/1.73  m2 in the intensive-therapy 
group than in the standard-therapy group (P  <  0.001), 
although only 38 participants in the intensive-therapy 
group and 32 in the standard-therapy group had two or 
more instances of eGFR <30 mL/min/1.73 m2 (P = 0.46). 
The frequency of macroalbuminuria at the final visit was 
significantly lower in the intensive-therapy group than in 
the standard-therapy group, and there was no between-
group difference in the frequency of end-stage renal dis-
ease or the need for dialysis. In addition, the INVEST 
study also showed no mortality reduction in patients 
with a desired systolic blood pressure <130 mmHg com-
pared to that in patients with systolic blood pressure 
130–139 mmHg [82].
Optimal blood pressure values have not been estab-
lished. However, in 2015, the ADA aligned its recommen-
dations with hypertension guidelines, recommending 
the maintenance of a systolic blood pressure lower than 
140  mmHg and diastolic pressure below 90  mmHg as 
goals for the treatment of hypertensive diabetic patients 
[59]. Similarly, the 8th Joint National Committee of 
Hypertension also recommends that blood pressure for 
diabetic patients and individuals with CKD should be 
<140/90 mmHg [79].
Additional positive phase 2 clinical studies with drugs 
that have hemodynamic actions such as endothelin 
antagonists and mineralocorticoid receptor antagonists 
have led to larger phase 3 trials with atrasentan and finer-
enone, respectively, in order to address if these drugs 
indeed delay the development of end-stage renal disease 
[83]. Positive findings with respect to new glucose-low-
ering agents such as sodium-dependent glucose trans-
porter 2 inhibitors may lead to a change in the way we 
treat diabetic individuals with or at risk of DKD. A num-
ber of other pathways are currently under active preclini-
cal investigation and hopefully over the next decade will 
lead to promising drug candidates for subsequent clinical 
trials [83].
DM and CKD present a significant correlation with 
increased cardiovascular risk. The risk of events in 
patients with CKD is considered equivalent to that in 
patients with a history of coronary disease. Therefore, the 
combination of these two conditions classifies the patient 
with DKD as presenting a very high risk for a cardiovas-
cular event. Considering the exacerbated cardiovascular 
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risk of these patients, kidney disease: improving global 
outcomes (KDIGO) does not recommend the use of rou-
tine low-density lipoprotein (LDL) cholesterol level test-
ing to identify patients to be treated or the objectives of 
the treatment [84].
The current recommendation indicates the use of 
statins as drugs of choice since their efficacy in primary 
and secondary prevention of cardiovascular events has 
been proven, regardless of LDL levels [76, 84]. However, 
the appropriate dosage remains controversial. While 
ADA recommends the use of statins in high doses for 
diabetic patients with risk factors for cardiovascular dis-
ease, KDIGO recommends the reduction of the dosage 
of statins in individuals with a GFR lower than 60/mL/
min/1.73  m2 [59, 76, 85, 86]. This recommendation is 
based on the reduction of renal excretions (valid for some 
statins) and associated comorbidities. However, no stud-
ies have shown an increase in adverse events using high 
doses of statins, and the prescription information of ator-
vastatin states that there is no need for a dose adjustment 
in patients with CKD [85]. On the other hand, it is known 
that patients with CKD have an increased risk of mus-
cle damage with the use of statins, therefore this group 
of patients should be monitored more carefully. Results 
of studies on the use of statins in individuals undergo-
ing dialysis, in whom the cardiovascular risk is very high, 
have been disappointing. Despite the high risk, the cardi-
oprotective effect of statins seems to be less efficient than 
in other populations. Therefore, the systematic use of 
statins in dialysis patients is not currently recommended, 
due to the lack of observed benefits of this intervention 
in different studies. However, diabetic patients on dialysis 
continue to receive this drug due to the extrapolation of 
the proven benefits of statins in the diabetic population 
in general.
DR (diabetic retinopathy) is a microvascular complica-
tion that can occur in type 1 and type 2 diabetic patients, 
and its prevalence is closely related to the duration of the 
disease. The prevalence of this complication increases 
with the duration of DM, affecting more than 60  % of 
patients with DM2 and more than 90 % of patients with 
type 1 DM after 20 years of illness [87]. DR is the most 
frequent cause of blindness in adults aged 20–74  years. 
The pathogenesis of DR is directly linked to chronic 
hyperglycemia, and diabetic kidney disease is an impor-
tant factor for an increased risk of DR incidence. DR and 
diabetic nephropathy are the two most common micro-
vascular complications in patients with DM; however, 
whether these complications are only related or directly 
affect each other, or if their progression necessarily 
occurs simultaneously, is unclear [88].
Diabetic patients can eventually develop proteinuria, 
without the presence of DR, or might proliferative DR 
without the presence of albuminuria. Klein et al. studied 
a group of normoalbuminuric patients with type 1 DM 
and found that 36 % of these individuals did not develop 
DR, 53  % had nonproliferative DR, 9  % had moderate 
to severe DR, and 2 % had severe DR [89]. On the other 
hand, the prevalence of DR in patients with diabetic 
nephropathy and macroalbuminuria is between 70 and 
90  %. Proliferative retinopathy is already considered a 
predictive factor for macroalbuminuria in type 1 diabetic 
patients. Some authors consider both microalbuminuria 
and DR to be predictor factors for the progressive loss of 
kidney function [90].
ADA recommends periodic fundus examinations for 
retinopathy to be treated in a timely manner, before 
it progresses to irreversible vision loss. Examinations 
should be conducted at least annually and can be con-
ducted more frequently depending on the degree of 
retinopathy [58].
Diabetic cardiovascular autonomic neuropathy
Diabetic autonomic neuropathy is a severe complication 
of DM and is associated with increased morbidity and 
mortality and decreased quality of life of the patients. 
Diabetic autonomic neuropathy can affect different sys-
tems. Diabetic cardiovascular autonomic neuropathy 
(DCAN) can manifest clinically as resting tachycardia, 
severe orthostatic hypotension, syncope, ischemia and 
asymptomatic myocardial infarction, systolic and dias-
tolic left ventricular dysfunction, increased risk for CKD, 
stroke, hyporesponsiveness to hypoglycemia, and sudden 
cardiac death [91].
The association between DCAN and kidney disease is 
also well established and corroborates with the increase 
in mortality rates in diabetic patients with CKD. Ewing 
et al. found an upto 53 % increased mortality in diabetic 
patients with autonomic neuropathy, compared to 15  % 
in diabetic patients with no dysautonomia. Moreover, 
half of all deaths in patients with autonomic neuropathy 
in this study occurred due to impaired renal function, 
with 29  % of these being sudden death [92, 93]. In the 
literature, the prevalence of autonomic neuropathy var-
ies between 21 and 73 % in the diabetic population. The 
prevalence of autonomic neuropathy ranges from 20 to 
80 % in patients with DKD, and affects 66 % of patients 
with advanced kidney disease and 50  % of patients on 
dialysis [94]. A recent study showed that DCAN presents 
an important relationship with CKD, albuminuria, and 
decline in renal function in patients with DM2 [95].
Treatment of dysautonomic manifestations is essen-
tially symptomatic. Special attention should be given to 
the intensification of glycemic control, with monitoring of 
hypoglycemia and changes in lifestyle, including diet and 
exercise [96]. Regarding drug treatment, fludrocortisone 
Page 12 of 21Pecoits‑Filho et al. Diabetol Metab Syndr  (2016) 8:50 
and the α1-adrenergic agonist midodrine are considered 
the drugs of choice in the treatment of DCAN. Erythro-
poietin is also considered a possible adjunctive drug to 
increase blood pressure through an increase in the num-
ber of erythrocytes and central blood volume, correc-
tion of anemia in patients with severe dysautonomia, and 
neurohumoral effects on wall and vascular tone.
Diabetic genitourinary autonomic neuropathy
Almost half of the patients with DM develop some degree 
of bladder dysfunction. This prevalence may be even 
higher in populations with advanced CKD who have DM 
for a long time, or it may be due to the uremic syndrome 
per se. Bladder dysfunction might result in varying degrees 
of impairment, ranging from a mild decrease in bladder 
sensitivity, reduced emptying perception, and alteration 
in contractility, to situations where there is an increase in 
bladder capacity, urinary retention, increased frequency of 
urinary tract infections, lithiasis, and renal failure [97].
The prevalence of sexual dysfunction in patients with 
CKD can range from 9 % in pre-dialysis patients to 70 % 
in dialysis patients [98]. In diabetic patients, erectile dys-
function occurs in 35–75 % of patients, 10–15 years ear-
lier than in non-diabetics. In diabetic patients with CKD, 
the most common causes of erectile dysfunction are 
organic and are due to vascular disease and neuropathy.
The initial treatment approach for erectile dysfunc-
tion in diabetic patients should be glycemic and meta-
bolic control of other associated complications. Specific 
measures of treatment include drug therapy (group of 
phosphodiesterase inhibitors: sildenafil, vardenafil, and 
tadalafil). Intracavernous or intraurethral drugs (papa-
verine, phentolamine, and prostaglandins) are also used, 
as well as penile prostheses and vacuum devices [96, 99]. 
However, the use of these drugs requires a more care-
ful evaluation of CKD because of an increased risk of 
arrhythmias and heart failure.
Nutritional recommendations for diabetic patients 
with CKD
As diabetic patients experience progressive loss of renal 
function, nutritional issues become more complex. On 
one hand, in addition to the existing limitations asso-
ciated with DM, specific restrictions are needed for 
patients with CKD, including restriction of protein, 
phosphorus, and potassium. On the other hand, patients 
with worsening uremic syndrome have a higher risk of 
protein-calorie malnutrition that needs to be identified 
and addressed by the medical team. Thus, nutritional 
monitoring is of utmost importance in this patient pop-
ulation. Standardized protocols should be avoided, and 
individualized care and monitoring of patients should be 
implemented.
Initially, patients should be evaluated based on their 
standard intake and clinical laboratory results. Then, a 
nutritional counseling plan should be designed based 
on nutritional guidelines that aid in the development of 
appropriate diets for patients, always considering indi-
vidual needs.
For the population of diabetic patients with CKD in the 
non-dialytic phase, the composition of macronutrients in 
the nutritional plan is described in Table 1
For patients with DKD, the ADA (2013) recommends a 
normoproteic diet (0.8–1.0 g/kg/day) in the early stages 
of CKD and <0.8  g/kg/day or <0.6  g/kg/day in the later 
stages of the disease (Table 1), with 50 % of protein intake 
presenting high biological value. Protein restriction 
aims to act simultaneously as a renoprotective measure, 
reducing both proteinuria and generation of protein cata-
bolic waste.
For patients with proteinuria >3  g/day, a low pro-
tein diet (0.6  g/kg/day) is recommended, as well as the 
replacement of 1  g of high biological value-protein for 
each gram excreted. It is important to highlight that pro-
vision of a diet low in protein should ensure an adequate 
energy supply. The recommendation for calorie intake 
is the same for patients with CKD without the presence 
of DM—30–35  kcal/kg/day. For overweight and obese 
patients, the calorie intake recommended should be indi-
vidualized, although it should not be <25  kcal/kg/day. 
Regarding glycemic control, the recommended amount 
of carbohydrates follows the recommendations for the 
general population (Table  1). The quantity and quality 
of carbohydrates in the diet and its effects on glycemic 
responses are well established. Sucrose, when consumed 
Table 1 Dietary plan macronutrient composition for  DKD 
in the non-dialysis stage. Source: adapted from the Brazil-
ian Diabetes Society (2014)
Macronutrients Recommended intake/day
Total carbohydrates 45–60 % of TEI (total energy intake)
Saccharose Up to 10 %
Fructose Not recommended its addition to food
Dietary fibers Minimum of 20 g/day or 14 g/1000 kcal
Total fat Up to 30 % of TEI
Saturated fatty acids (SFA) <7 % of TEI
Trans fatty acids (TFA) ≤2 g
Polyunsaturated fatty acids 
(PUFAs)
Up to 10 % of TEI
Monounsaturated fatty acids 
(MUFA)
Supplemented individually
Cholesterol <200 mg/day
Proteins 0.8–1.0 g/kg/day in the early stages of 
disease and <0.8 g/kg/day in the final 
phases
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in amounts equivalent to that of other carbohydrates, 
increases blood glucose level equivalently; therefore, 
sucrose can be consumed in a nutritionally healthy diet 
as long as its intake does not exceed 10 % of daily caloric 
consumption. The use of sweeteners, although indi-
cated, is not essential for the treatment of DM. The use of 
sweeteners can provide beneficial effects, such as weight 
loss in overweight or obese patients, due to their low 
caloric value, thus also reducing insulin.
In addition, adequate intake of food rich in complex 
carbohydrates (dietary fibers) should be encouraged, 
since this consumption is associated with glycemic con-
trol, satiety, and lipid absorption, thus also contributing 
to weight control. Although consumption of dietary fib-
ers, especially in the soluble fraction, should be encour-
aged, it is important to highlight that, in general, foods 
rich in this nutrient fruits, vegetables, and legumes—are 
also sources of potassium, a mineral for which intake 
should be controlled in patients with CKD. Main sources 
of dietary fibers with low potassium levels are fruits such 
as pineapple, apple, pear and strawberry, and vegetables 
such as carrot, watercress, lettuce, escarole, cucumber 
and cabbage.
One method that can be used to control blood glu-
cose in these patients is carbohydrate counting, in which 
grams of this macronutrient obtained from meals are 
recorded throughout the day. This method is efficient in 
food control and the use of insulin, and its orientation 
should be individualized.
The recommendations for lipid consumption in dia-
betic patients are the same as those for individuals with 
cardiovascular diseases (Table 1), since both patients are 
at high risk for cardiovascular events. According to the 
Guidelines of the SBD (2014), the goals for lipid con-
trol in diabetic nephropathy include serum LDL cho-
lesterol levels <100 or <70 mg/dL in the presence of any 
cardiovascular disease and levels of serum triglycerides 
<150  mg/dL and high-density lipoprotein cholesterol 
>40 mg/dL for men and >50 mg/dL for women.
In an interesting study conducted by Cardenas et  al. 
(2004) [100], it was identified that, in patients with DM 
with different degrees of renal disease, a greater intake 
of polyunsaturated fatty acids and lower intake of satu-
rated fatty acids, as well as a higher ratio of unsaturated 
and saturated fatty acids, promoted a better evolution 
of diabetic nephropathy. In the same study, it was found 
that patients with worsening symptoms consumed 
higher amounts of saturated fatty acids during the 7-year 
follow-up.
Considering that arterial hypertension is a factor for 
the progression of diabetic nephropathy, blood pres-
sure control is essential for the treatment of the disease. 
The American Dietetic Association (2013) recommends 
a sodium intake <1500  mg/day, which corresponds to 
3.75 g/day of salt. In a study conducted by Houlihan et al. 
(2012) [101], a diet with 1.2–1.7  g of sodium promoted 
similar effects to the inclusion of a second antihyperten-
sive drug in the treatment of hypertension.
Pharmacological treatment: non‑insulin antidiabetic 
agents
Control of blood glucose levels in diabetic patients with 
CKD in different stages is not adequately standardized. 
Due to the increased risk of hypoglycemia [102] in these 
patients, insulin has been considered the safest anti-
diabetic agent. However, new non-insulin antidiabetic 
agents proved to be safe and effective. New revisions and 
guidelines are being published to guide the glycemic con-
trol of patients with CKD [70, 103, 104]. Regarding the 
therapeutic goals, the benefits of strict control of blood 
glucose levels in recently diagnosed diabetic patients 
[105] is not observed in diabetic patients with the disease 
for a long time and who have already developed cardio-
vascular complications [60, 63, 106], typical of diabetic 
patients with CKD. For example, the ACCORD trial 
noted an increase in the overall mortality of 22 % in dia-
betic patients with the disease for an average of 10 years 
with a history of cardiovascular diseases, who received 
intensive glucose control, and aimed for HbA1c of 6.5 % 
compared to that in the control group, which was to 
seeking to achieve HbA1c of 7.3 %. This is explained by 
the increased risk of hypoglycemia episodes associated 
with a more intensive management of DM and the fact 
that these patients are more susceptible to the deleterious 
effects of hypoglycemia, such as activation of the sym-
pathetic nervous system. However, there are benefits of 
controlling blood glucose levels in diabetic patients with 
CKD in terms of reducing mortality rates [107], inhibit-
ing progression of CKD [107, 108], and diminishing albu-
minuria [108]. Nevertheless, the therapeutic goals should 
be individualized and it should be considered that HbA1c 
overestimates glycemic control in patients with CKD 
[109]. Below we discuss several aspects related to CDK 
of noninsulin antidiabetic agents that are not available in 
our environment.
Metformin
Metformin acts primarily in the liver, decreasing the 
production of hepatic glucose. Therefore, it is associated 
with low risk of hypoglycemia. This drug has been used 
for several years and has proven to reduce cardiovascu-
lar events [105] and contribute to mild weight reduction. 
Thus, it is considered the first choice drug in the treat-
ment of DM2 [110]. This drug is excreted by the kidney 
and therefore, in patients with CKD, it may accumulate 
and increase the risk of lactic acidosis, which is a side 
Page 14 of 21Pecoits‑Filho et al. Diabetol Metab Syndr  (2016) 8:50 
effect of this drug. Hence, several authors do not recom-
mend the use of metformin in women with creatinine 
levels >1.4 mg/dL and men with levels >1.5 mg/dL [111]. 
Others recommend halving the dose in patients with a 
creatinine clearance of 30–45 mL/min/1.73 m2 and sus-
pension of the drug in patients with <30 mL/min/1.73 m2 
[112]. The relationship between metformin accumulation 
and lactic acidosis is not well documented [113]. Fac-
tors such as acidosis, hypoxia, infection, and dehydration 
are also associated with the advent of lactic acidosis in 
patients receiving metformin, and in these situations, the 
drug should be suspended temporarily.
Sulfonylureas
Sulfonylureas act in pancreatic β-cells, releasing insulin. 
The effectiveness of the class depends on the stores of 
β-cells, which decreases with the length of the DM. The 
action of these drugs is independent of glucose levels. 
Therefore, hypoglycemic episodes are more severe and 
frequent with the use of sulfonylureas [114]. In patients 
with CKD, the use of short-acting sulfonylureas metab-
olized in the liver, including glipizide, gliclazide, and 
glimepiride, is recommended. However, the use of this 
class should be avoided in patients with creatinine clear-
ance <45 mL/min/1.73 m2. Sulfonylureas can bind to pro-
teins and are not eliminated by dialysis.
Glinides
Similarly, glinides, such as repaglinide and nateglinide, 
act in pancreatic β-cells, releasing insulin. However, these 
drugs have a shorter half-life and cause less hypoglyce-
mia [115]. Glinides are metabolized predominantly in 
the liver. These drugs should be used three times a day 
before meals and can be used in patients with a creati-
nine clearance <30 mL/min/1.73 m2, although with care 
and a reduced dosage [103].
Glitazones
Glitazones, such as pioglitazone and rosiglitazone, 
increase insulin sensitivity in muscle and adipose tissues 
by acting on PPAR-ɣ receptors. These drugs are metabo-
lized in the liver, do not accumulate in CKD, and do not 
cause hypoglycemia, even in patients undergoing dialysis. 
They are associated with water and salt retention, which 
limits the use of this class in CKD. It has been shown that 
the use of rosiglitazone is associated with an increased 
risk of myocardial infarction [116] and increased cardio-
vascular mortality in patients undergoing hemodialysis 
[117]. Therefore, pioglitazone has been used more fre-
quently. Glitazones are also associated with a higher risk 
of fractures and bladder cancer. Despite the low risk of 
hypoglycemia, this class of drugs should be avoided in 
patients with CKD.
Alpha‑glucosidase inhibitors
Acarbose acts in the gut by inhibiting alpha-glucosidase, 
the enzyme responsible for digesting carbohydrates. It 
does not cause hypoglycemia. Its main side effect is flatu-
lence. In CKD, its use should be avoided, since it accu-
mulates and can cause hepatotoxicity [118].
Sodium‑glucose cotransporter type 2 inhibitors
In the glomeruli, about 180 g of glucose per day is filtered, 
and nearly all is reabsorbed in the S1 segment of the 
proximal tubule by sodium-glucose cotransporters. Of 
these, type 2 cotransporters are the most important [119]. 
Drugs that inhibit this transporter have been developed, 
such as dapagliflozin, canagliflozin, and empagliflozin. 
These drugs block reabsorption of glucose and sodium in 
the proximal tubule, contributing to improved glycemic 
control, with no risk of hypoglycemia, as well as hyper-
tension control, due to increased natriuresis. The use of 
these drugs is associated with a higher incidence of geni-
tal infection. This hypoglycemic class is not indicated in 
patients with a creatinine clearance <45 mL/min/1.73 m2 
[120], but recent studies show a potential application in 
the lower (30  ml/min) GFR range. Recent data suggests 
cardiovascular benefits of this class, opening opportuni-
ties for a broader application of SGLT-inhibitors [120].
Peptide‑1 receptor agonists similar to glucagon (GLP‑1 RA)
GLP-1 is an incretin secreted in the gastrointestinal tract 
in response to food intake. It acts on pancreatic β-cells, 
releasing insulin, and in pancreatic α-cells, inhibiting the 
secretion of glucagon in a glucose-dependent manner; 
therefore, GLP-1 controls blood glucose with a lower 
risk of hypoglycemia. Moreover, it slows gastric empty-
ing and decreases appetite through a central mecha-
nism, thus contributing to weight loss. GLP-1 receptor 
agonists, such as exenatide and liraglutide, are peptides 
with a structure similar to endogenous GLP-1. However, 
these drugs are resistant to enzyme dipeptidyl pepti-
dase-4 catabolism. The route of administration is subcu-
taneous. Since they are peptides, they are filtered in the 
glomeruli and degraded in the proximal tubules, simi-
lar to the process associated with insulin. There is little 
knowledge regarding this class of antidiabetic drugs in 
CKD, although gastrointestinal effects are exacerbated 
in patients with CKD, including nausea, vomiting, and 
diarrhea. Moreover, there have been reported cases of 
acute renal injury with the use of exenatide in patients 
with CKD [121]. Therefore, while acquiring further 
knowledge about this class, it is suggested that careful 
attention be paid to their use in patients with creatinine 
clearance 45–60 mL/min/1.73 m2. Also, its use should be 
avoided in patients with a creatinine clearance <45 mL/
min/1.73 m2 [103].
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Dipeptidyl peptidase‑4 (DPP‑4) inhibitors
DPP-4 is an enzyme that degrades GLP-1 and GIP incre-
tins. Therefore, DPP-4 inhibitors increase the concen-
trations of GLP-1 and GIP, which, as mentioned above, 
act in pancreatic β-cells by releasing insulin, and in pan-
creatic α-cells, inhibiting the secretion of glucagon in a 
glucose-dependent manner, thus controlling blood glu-
cose with no risk of hypoglycemia. The greatest effect of 
DPP-4 inhibitors is in the postprandial period, when the 
levels of glucose are elevated. DPP-4 inhibitors are also 
known as gliptins. Four gliptins are available: vildaglip-
tin, sitagliptin, saxagliptin, and linagliptin. This antidia-
betic class is becoming more important among diabetic 
patients with CKD, due to their excellent tolerability 
profile [122–126]. Vildagliptin, sitagliptin, and saxaglip-
tin are excreted by the kidney and require dosage adjust-
ment in patients with creatinine clearance <50  mL/
min/1.73  m2. For example, vildagliptin, which is used 
at a dosage of 50 mg twice a day, should be used at the 
same dose, but as a single daily administration in patients 
with creatinine clearance <50 mL/min/1.73 m2, including 
patients with Stage 5 CKD [124]. Linagliptin has no renal 
excretion and therefore does not require adjustment for 
renal function.
Until recently, the arsenal of noninsulin antidiabetic 
agents was not safe to be used in diabetic patients with 
CKD, and insulin therapy was started early, causing psy-
chological distress to patients and families. Nowadays, 
there are new noninsulin agents, DPP-4 inhibitors in 
particular, which present a low risk of hypoglycemia and 
can be used in patients with DM2 with CKD. However, 
further studies are required to confirm the safety of these 
new agents in this population. Table  2 summarizes the 
recommendations for the use of noninsulin antidiabetic 
agents for noninsulin patients based on international 
guidelines [70, 103, 104].
Pharmacological treatment of DM in CKD: insulin therapy
The kidney plays an important role in clearing insulin 
from the systemic circulation and two distinct pathways 
have been described; one involves glomerular filtration 
and subsequent insulin absorption by proximal tubu-
lar cells through endocytosis; and the other is related 
to insulin diffusion through peritubular capillaries and 
their connection to the contraluminal tubular membrane, 
especially from the distal half of the nephron. Therefore, 
insulin is transported by lysosomes and metabolized 
to amino acids that are released by diffusion in peritu-
bular vessels, and final degradation products are then 
reabsorbed [127–129]. Endogenous insulin has a mean 
plasma half-life of only 6  min and it is almost cleared 
from the circulation within 10–15  min (Fig.  3a). Except 
for the portion of insulin bound to its receptors on the 
target cells, the remainder is degraded mainly in the liver, 
to a lesser extent in kidney and muscle and slightly in 
most other tissues. In contrast, exogenous insulin does 
not undergo the first-pass effect in the liver, the kidney 
plays an important role in the metabolism and clear-
ance of circulating insulin in patients with renal failure 
(Fig. 3b). As a consequence, with the progression of CKD, 
insulin clearance decreases, thus requiring a dose reduc-
tion in order to avoid hypoglycemia [130, 131].
The pharmacokinetics of commercially available insu-
lin in diabetic patients with reduced glomerular filtra-
tion rate has been evaluated for small number of studies. 
Although the profile of these patients requires less insu-
lin, several authors suggest a reduction of the dose of 
insulin when GFR is between 10–50  mL/min, around 
Table 2 Recommendations for the use of noninsulin antidiabetic agents in CKD
Antidiabetic Agents Recommendations in CKD
Metformin With creatinine clearance 30–45 mL/min/1.73 m2, halve the dose and suspend the drug 
when the creatinine clearance is <30 mL/min/1.73 m2
Sulfonylureas Use drugs with a short duration of action and suspend the drugs when the creatinine 
clearance is <45 mL/min/1.73 m2
Glinides These can be used in patients with CKD, although with care when the creatinine clearance 
is <30 mL/min/1.73 m2
Glitazones (pioglitazone) Their use is associated with water and salt retention, which limits their use in CKD
Alpha‑glucosidase inhibitors (acarbose) Their use should be avoided in CKD, due to risk of drug accumulation and consequent 
hepatotoxicity
Sodium‑glucose cotransporter type 2 inhibitors Their use is not indicated with a creatinine clearance <30 mL/min/1.73 m2
Peptide‑1 receptor agonists similar to glucagon (GLP‑1 RA) Little knowledge in CKD. Gastrointestinal effects are exacerbated in patients with CKD. 
Use with caution with a creatinine clearance 45–60 mL/min/1.73 m2 and avoid its use in 
patients with a creatinine clearance <45 mL/min/1.73 m2
Dipeptidyl peptidase‑4 (DPP‑4) inhibitors Low risk of hypoglycemia. These can be used in CKD. With a creatinine clearance <50 mL/
min/1.73 m2, dosage adjustments should be made for vildagliptin, sitagliptin, and saxa‑
gliptin. The dose of linagliptin does not require adjustment in CKD
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25 % of total daily dose and 50 % for a GFR <10 mL/min, 
regardless of the type of insulin used [132].
Insulins are classified according to their action profile 
(Table  3). Thus, the first exogenous insulins developed 
to control blood sugar, NPH (Neutral Protamine Hage-
dorn) and Regular insulin are labeled as having an inter-
mediate- and rapid-acting profile, respectively. One has 
a peak activity 4–7 h after subcutaneous injection, while 
the other one is used before meals in order to reduce the 
peak of hyperglycemia after the ingestion of carbohy-
drates. However, its onset of action is between 30  min 
and 1 h and it must be applied around 30–45 min before 
the meal. The insulin analogs, produced by recombinant 
DNA technology, are classified as (1) short-acting (lispro, 
aspart, and glulisine insulin), (2) long-acting (glargine, 
detemir), or (3) ultra-long-acting (degludec). The associa-
tion between the short-acting and the long- or ultra-long-
acting insulin analogs enables physiological simulation of 
insulin secretion; this therapeutic association has been 
termed basal-bolus insulinization.
Due to its pharmacokinetic profile with a stable half-
life and duration of action of about 24  h, glargine insu-
lin can be prescribed once a day. To date, few studies 
have been published on the use of glargine insulin in 
patients with renal failure, and its use appears to be safe, 
with a reduction in HbA1c in a short period of time 
[133]. In hospitalized patients with a GFR <45 mL/min, 
the reduction of the dosage calculated according to the 
body weight was shown to be effective in diminishing the 
number of hypoglycemic events by 50  %, without com-
promising metabolic control [134]. Detemir insulin has 
an onset of drug action of 1 h, and its effect lasts 12–24 h. 
Thus, it is recommended that this drug be used in two 
daily doses, with intervals of about 12 h. However, some 
patients could present different sensitivity along the day, 
and for this subgroup of patients a single-a-day dose may 
be enough to maintaining adequate glycemic control in 
the postprandial period [135, 136]. A recent study [137] 
demonstrated the need for dose reduction, for both glar-
gine and detemir insulin, in patients with renal function 
impairment. In this case, the dose of glargine and detemir 
insulin was 29.7 and 27.3 % lower in individuals with GFR 
<60 mL/min than in those with GFR >90 mL/min. Deglu-
dec insulin, with an ultra-long-action profile, has recently 
Fig. 3 Schematic presentation of the clearance of insulin. a endogenous insulin and b exogenous insulin. Adapted from Iglesias and Díez [130]
Table 3 Insulin pharmacokinetic profiles
Insulin type Onset Peak Duration of action
Rapid‑acting profile
Regular 30 min 2–4 h 5–7 h
Short‑acting profile
Lispro
Aspart
Glulisine
5–15 min 60–90 min 3–4 h
intermediate‑acting profile
NPH* 2 h 6–10 h 13–20 h
Long‑acting profile
Glargin ~2 h Flat 20–24 h
Detemir ~2 h Less‑pronounced peak 6–24 h
Ultra‑long‑acting profile
Degludec 20–40 min Flat ~42 h
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been approved to be commercialized, and only one study 
in patients with different stages of renal failure and ter-
minal CKD has been published, showing no statistical 
significant differences in absorption or release profiles 
when compared to individuals with normal renal func-
tion. Thus, degludec insulin does not require dose adjust-
ments due to the loss of kidney function [138].
As shown on Table 3, the insulin analogs lispro, aspart, 
and glulisine have short durations and very similar phar-
macokinetic profiles [139]. Because lispro insulin was the 
first analog investigated, there are a number of studies 
in patients with CKD [140–142] showing it has a ben-
eficial effect in reducing glomerular hyperfiltration and 
renal effects of hyperglycemia triggered by meals; these 
effects are possibly related to an antagonistic effect on 
insulin-like growth factor-1 [140]. Furthermore, the use 
of lispro insulin was associated with improved glycemic 
control and quality of life in patients on hemodialysis 
by end-stage diabetic renal disease [141, 142]. The gluli-
sine and aspart insulin also had their safety and efficacy 
demonstrated in controlling postprandial hyperglyce-
mia in patients with DM2 and severe renal failure [143]. 
No change in the pharmacokinetic of these drugs was 
observed [144].
Regardless of insulin being considered the best choice 
for glycemic control in patients with renal impairment, its 
prescription must be based on some guidelines, such as: 
(1) individualization of the therapy; (2) frequent reassess-
ment of prescription or adjustment of doses for the glo-
merular filtration rate; (3) basal-bolus insulin regimens, 
prescribing intermediate- or long-acting profile insu-
lin, as basal insulin, to keep the levels of blood glucose 
stable on post-absorptive period, associated with short-
acting profile insulin to promote adequate carbohydrates 
metabolism and control of postprandial glycaemia; and 
(4) blood glucose monitoring and frequent adjustment of 
insulin therapy based on individual response [145]. Few 
studies have reported specific information on the differ-
ences in action profiles, half-life, metabolism, and clear-
ance of different insulin types available that are adjusted 
for the different stages of CKD; such studies would allow 
the prescription of more effective therapeutic regimens, 
minimizing risk of hypoglycemia, which is potentially 
more harmful in this population. Therefore, the treat-
ment should be individualized based on factors such as 
the presence of complications, associated diseases, dis-
ease management ability, stage and duration of CKD, and 
previous glycemic control [146–148]. In addition, there 
should be participation of a multidisciplinary team con-
sisting of nephrologists, endocrinologists, nutritionists, 
and nurses. This approach has proved to be an effective 
strategy in achieving individual glycemic optimal values, 
reducing the rate of progression of kidney disease and 
other complications associated with DM2, and improving 
the quality of life of patients with DKD.
Conclusion
The relationship between DM and DKD is more com-
plicated than the predisposition of a diabetic patient to 
develop kidney disease and the negative impact on mor-
bidity and mortality of patients with kidney disease and 
DM. Recently, the kidney has been recognized as being 
directly involved in the pathogenesis of DM because of 
its ability to regulate glucose reabsorption as well as to 
determine insulin half-life and resistance. In addition, it 
is now clear that glomerular filtration provides a safe and 
efficacious target for many hypoglycemic drugs. Thus, 
understanding the renal physiology and pathophysiol-
ogy of DKD has become essential to all specialties treat-
ing diabetic patients. Disseminating this knowledge and 
detailing the evidence will be important to initiate break-
through research and to encourage proper treatment of 
this group of patients.
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